Persistence Market Research is released upcoming report on title "Next-Generation Antibody Therapeutics Market: Global Industry Analysis and Forecast to 2020".
New York, NY -- (SBWIRE) -- 03/23/2015 -- Next-generation antibody based therapeutics refers to the use of new and improved therapeutic antibody to create innovative medicines for the treatment of various diseases. Next-generation antibody therapeutics is developed clinically by biotechnology and pharmaceutical companies for various diseases indication. These new therapeutic antibodies are developed with the special features such as increased selectivity and enhance efficacy. Technological advancement such as antibody drug conjugates (ADCs), success of monoclonal antibody (MAb) and antibody-derived therapeutics and increasing demand for biological drugs for the treatment for various chronic diseases are some of the main factors which helps to drive the market. On the basis of technology, next-generation antibody therapeutics market can be segmented into engineered antibodies, bispecific antibodies (bisAbs), antibody-drug conjugates (ADCs), antibody fragments and antibody-like proteins and biosimilar antibody products. ADCs are composed by linking of an antibody with cytotoxic drugs. On the basis of platform, next-generation antibody therapeutics market can be segmented into BioWa. Glycart and xencor. On the basis of therapeutic area, next-generation antibody therapeutics market can be segmented into oncology, autoimmune/inflammatory, haemostasis, ocular disorders, various infectious diseases and others.
Buy Full Report: http://www.persistencemarketresearch.com/market-research/next-generation-antibody-therapeutics-market.asp
North America, followed by Europe, has the largest market for next-generation antibody therapeutics due to technological advancement in antibody therapies, increasing research and development activities in drug development, rise in healthcare expenditure and government initiatives in this region. Asia is expected to experience high growth rate in the next-generation antibody therapeutics market in next few years due to increasing incidence of chronic diseases, rise in demand for better healthcare facilities, growing R&D activities and new antibody technologies in the region.
Emerging antibody technology, rise in incidence of various chronic diseases, government initiatives, new drug innovations, increasing adoption of therapeutic antibodies and antibodies, growing research and development activities for new therapies are some of the major factors that are driving the global market for next-generation antibody therapeutics. In addition, advantages of traditional monoclonal antibodies, increasing healthcare spending and rise in use of monoclonal antibody (Mab) and antibody-derived therapies by pharmaceutical companies are driving the global market for next-generation antibody therapeutics. However, strict government regulation, huge cost and time involvement in R&D activities and preference of older generation drug therapies are some of the factors restraining the growth for global next-generation antibody therapeutics market.
Growing demographics and economies in the developing countries such as India and China is expected to lead the growth in next-generation antibody therapeutics market in Asia. In addition, emerging antibody technologies, continuous improvement in therapeutic antibody, rise in incidence of various diseases, increasing demand for better healthcare facilities and rapid growth in biosimilar antibodies and engineered antibodies are expected to offer new opportunities for global next-generation antibody therapeutics market. Increasing number of collaborations and partnerships, rise in number of mergers and acquisitions and new product launches along with technological advantages are some of the latest trends that have been observed in global next-generation antibody therapeutics market. Some of the major companies operating in the global next-generation antibody therapeutics market are F. Hoffmann-La Roche Ltd, Kyowa Hakko Kirin, ImmunoGen, Bristol-Myers Squibb, Seattle Genetics, MedImmune and BioWa. In addition, some other companies operating in global next-generation antibody therapeutics market are Amgen, Bayer, Pfizer, Biogen Idec and Xencor.
Request Full Toc: http://www.persistencemarketresearch.com/toc/3713
Key points covered in the report:
1) Report segments the market on the basis of types, application, products, technology, etc (as applicable)
2) The report covers geographic segmentation
3) The report provides the market size and forecast for the different segments and geographies for the period of 2010 to 2020
4) The report provides company profiles of some of the leading companies operating in the market
The report also provides porters five forces analysis of the market.
Visit our blog at: http://pmrblog.com/
About Persistence Market Research
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.
PMR stands committed to bringing more accuracy and speed to clients' business decisions. From ready-to-purchase market research reports to customized research solutions, PMR's engagement models are highly flexible without compromising on its deep-seated research values.